Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Announces Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
Top-line Phase 1 Selinexor Data in Combination with Chemotherapy Show Encouraging Early Efficacy in Patients with Ovarian and Endometrial Cancers Top-line Phase 1 KPT-9274 Data Show a Manageable Safety Profile and Early Signals of Anti-Tumor Activity NEWTON, Mass., Sept.
View HTML
Toggle Summary Karyopharm Announces the Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting, taking place September 8-12, 2017 in
View HTML
Toggle Summary Karyopharm Therapeutics to Participate in Upcoming Investor Conferences
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: The Baird 2017 Global
View HTML
Toggle Summary Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress
− Pivotal Phase 3 BOSTON Study Underway - − Updated Phase 1b/2 STOMP Data Expected by Year End 2017; Top-line Phase 2b STORM Data Expected by April 2018 - − Phase 2 SEAL Hazard Ratio Expected in September/ October 2017 , Along with Other Pipeline Program Updates During the Second Half of 2017 - −
View HTML
Toggle Summary Karyopharm to Report Second Quarter 2017 Financial Results on August 8, 2017
Conference Call Scheduled for Tuesday, August 8, 2017 at 8:30 a.m. ET
View HTML
Toggle Summary Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting
Objective Response Rate Increases to 33.3% Overall and is 35% in Patients with "Double- or Triple-Hit" DLBCL With Additional Responders, Median Duration of Response Remains Greater than 7 Months Top-Line Data from SADAL Study Expected in the Second Half of 2018 NEWTON, Mass., June 23, 2017 (GLOBE
View HTML
Toggle Summary Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Enrollment Projected To Be Complete in 2018; Top-Line Data Expected in 2019
View HTML
Toggle Summary Karyopharm Therapeutics to Participate in Upcoming Investor Conferences
NEWTON, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: The Jefferies 2017 Global
View HTML
Toggle Summary Karyopharm's Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting
Phase 2b SADAL Data Also Selected for Poster Presentation at ICML 2017
View HTML
Toggle Summary Karyopharm Reports First Quarter 2017 Financial Results and Highlights Recent Progress
− Pivotal Phase 3 BOSTON Study Expected to Commence in May 2017 — − Secured $52.2 Million Through Recent Equity Financing and ATM Facility — − Conference Call Scheduled for Today at 8:30 a.m. ET − NEWTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.
View HTML